A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.

Vince B C BiemansEdo SavelkoulRuben Y GabriëlsMelek SimsekGerard DijkstraMarieke J PierikRachel L WestNanne K H de BoerFrank Hoentjen

Published in: Alimentary pharmacology & therapeutics (2020)

Nineteen percent of IBD patients with prior failure to conventional thiopurines due to adverse events discontinued therapy with tioguanine or LDTA due to adverse events. Either therapy may be considered before escalating to biological therapy.

Keyphrases

low dose
ejection fraction
end stage renal disease
newly diagnosed
prognostic factors
bone marrow
patient reported